KR20250042167A - 항미생물 화합물, 조성물, 및 그의 용도 - Google Patents

항미생물 화합물, 조성물, 및 그의 용도 Download PDF

Info

Publication number
KR20250042167A
KR20250042167A KR1020257005507A KR20257005507A KR20250042167A KR 20250042167 A KR20250042167 A KR 20250042167A KR 1020257005507 A KR1020257005507 A KR 1020257005507A KR 20257005507 A KR20257005507 A KR 20257005507A KR 20250042167 A KR20250042167 A KR 20250042167A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
present disclosure
acceptable salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257005507A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 에이. 케이츠
랜돌프 비. 슬릿
스티븐 파킨슨
Original Assignee
레이크우드 아메덱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레이크우드 아메덱스, 인크. filed Critical 레이크우드 아메덱스, 인크.
Publication of KR20250042167A publication Critical patent/KR20250042167A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
KR1020257005507A 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도 Pending KR20250042167A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762470039P 2017-03-10 2017-03-10
US201762470025P 2017-03-10 2017-03-10
US62/470,025 2017-03-10
US62/470,039 2017-03-10
PCT/US2018/022068 WO2018165673A1 (en) 2017-03-10 2018-03-12 Antimicrobial compounds, compositions, and uses thereof
KR1020247022774A KR102772428B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022774A Division KR102772428B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20250042167A true KR20250042167A (ko) 2025-03-26

Family

ID=63446316

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197029037A Active KR102317158B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도
KR1020227039954A Active KR102684529B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도
KR1020217031132A Active KR102621577B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도
KR1020257005507A Pending KR20250042167A (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도
KR1020247022774A Active KR102772428B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020197029037A Active KR102317158B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도
KR1020227039954A Active KR102684529B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도
KR1020217031132A Active KR102621577B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247022774A Active KR102772428B1 (ko) 2017-03-10 2018-03-12 항미생물 화합물, 조성물, 및 그의 용도

Country Status (14)

Country Link
US (5) US20210139522A1 (enExample)
EP (2) EP4272832A3 (enExample)
JP (3) JP6917078B2 (enExample)
KR (5) KR102317158B1 (enExample)
CN (2) CN110612143B (enExample)
AU (5) AU2018230805B2 (enExample)
BR (2) BR122021004504B1 (enExample)
CA (1) CA3055932A1 (enExample)
DK (1) DK3592430T3 (enExample)
ES (1) ES2987873T3 (enExample)
FI (1) FI3592430T3 (enExample)
MX (1) MX391911B (enExample)
PT (1) PT3592430T (enExample)
WO (2) WO2018165673A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
BR112021006954A2 (pt) * 2018-10-17 2021-07-20 Lakewood Amedex, Inc. métodos e composições para tratar mucosite oral
CA3139365A1 (en) * 2019-06-06 2020-12-10 Aligos Therapeutics, Inc. Heterocyclic compounds
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
MX2023008829A (es) * 2021-07-22 2023-08-10 Lakewood Amedex Inc Metodos para preparar bisfosfocinas.
US20240245717A1 (en) * 2022-12-14 2024-07-25 Lakewood Amedex, Inc. Antiviral compounds, compositions, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US7868162B2 (en) 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
ATE287897T2 (de) * 1999-02-12 2005-02-15 Sankyo Co Analoga von nukleosiden und oligonukleotiden
US6825348B2 (en) * 2002-06-25 2004-11-30 Academia Sinica Antiviral compounds
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
CN101724001A (zh) * 2008-10-24 2010-06-09 汪明 一类药用嘧啶衍生物的合成方法
WO2010054058A1 (en) * 2008-11-06 2010-05-14 Ambit Bioscience Corporation Imidazolothiazole compounds as modulators of protein kinase
US8884000B2 (en) * 2010-02-17 2014-11-11 Albert Einstein College Of Medicine Of Yeshiva University Saporin-L1 inhibitors and uses thereof
EP2601205A2 (en) * 2010-08-03 2013-06-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Guanine nucleotide derivatives for treating bacterial infections
WO2012060482A1 (ko) * 2010-11-02 2012-05-10 서울대학교 산학협력단 Ｃｄｋ를 저해하는 피롤로피리미디논 카복사미드 유도체 또는 이의 약학적으로 허용가능한 염, 이를 유효성분으로 함유하는 간세포암의 예방 또는 치료용 약학적 조성물
EP2912050A4 (en) * 2012-10-29 2016-09-28 Cocrystal Pharma Inc PYRIMIDIN NUCLEOTIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3027636B1 (en) * 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US8889701B1 (en) * 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
MX2019014772A (es) * 2017-06-12 2020-02-07 Lakewood Amedex Inc Formulaciones en gel de bisfosfocinas y usos de estas.

Also Published As

Publication number Publication date
KR102772428B1 (ko) 2025-02-27
WO2018165673A1 (en) 2018-09-13
AU2022256175B2 (en) 2023-09-28
AU2018230805A2 (en) 2019-10-31
MX2019010695A (es) 2022-04-28
CN110612143B (zh) 2021-07-02
EP3592430A1 (en) 2020-01-15
KR102317158B1 (ko) 2021-10-25
AU2022256216A1 (en) 2024-05-09
JP7315248B2 (ja) 2023-07-26
BR112019018615A2 (pt) 2020-04-07
NZ798061A (en) 2025-05-30
AU2023285791A1 (en) 2024-01-18
JP2021169492A (ja) 2021-10-28
KR20210122898A (ko) 2021-10-12
KR102684529B1 (ko) 2024-07-12
KR20240114768A (ko) 2024-07-24
EP3592430B1 (en) 2024-06-26
US20190330255A1 (en) 2019-10-31
AU2021201251B2 (en) 2022-07-21
DK3592430T3 (da) 2024-09-16
CN113476469B (zh) 2024-04-19
AU2022256175A1 (en) 2022-11-24
FI3592430T3 (fi) 2024-08-26
KR20220159474A (ko) 2022-12-02
CN110612143A (zh) 2019-12-24
US20200354395A1 (en) 2020-11-12
AU2021201251A1 (en) 2021-03-18
AU2018230805B2 (en) 2020-11-26
AU2018230805A1 (en) 2019-10-24
JP2023126939A (ja) 2023-09-12
EP4272832A2 (en) 2023-11-08
US10711028B2 (en) 2020-07-14
AU2023285791B2 (en) 2025-11-20
CN113476469A (zh) 2021-10-08
JP6917078B2 (ja) 2021-08-11
US20180258128A1 (en) 2018-09-13
KR20190127782A (ko) 2019-11-13
AU2022256216B2 (en) 2024-06-27
US10981943B2 (en) 2021-04-20
US20190330256A1 (en) 2019-10-31
BR122021004504B1 (pt) 2022-08-23
WO2018165675A1 (en) 2018-09-13
NZ757711A (en) 2024-03-22
BR112019018615B1 (pt) 2021-11-16
ES2987873T3 (es) 2024-11-18
US20210139522A1 (en) 2021-05-13
JP2020510085A (ja) 2020-04-02
US10752651B2 (en) 2020-08-25
KR102621577B1 (ko) 2024-01-05
EP3592430A4 (en) 2021-01-13
PT3592430T (pt) 2024-09-05
EP4272832A3 (en) 2023-11-22
CA3055932A1 (en) 2018-09-13
MX391911B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
KR102772428B1 (ko) 항미생물 화합물, 조성물, 및 그의 용도
US20240391944A1 (en) Antimicrobial compounds, compositions, and uses thereof
US11377468B2 (en) Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en) Antimicrobial compounds, compositions, and uses thereof
HK40060969A (en) Antimicrobial compounds, compositions, and uses thereof
HK40060969B (zh) 抗微生物化合物、组合物及其用途
HK40018480B (en) Antimicrobial compounds, compositions, and uses thereof
HK40018480A (en) Antimicrobial compounds, compositions, and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250219

Application number text: 1020247022774

Filing date: 20240708

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250320

Comment text: Request for Examination of Application

PG1501 Laying open of application